N-heterocyclic compounds and methods of use thereof

Novel N-heterocyclic compounds targeting calcineurin address the limitations of traditional CNIs by reducing side effects and improving patient adherence in treating inflammatory-related diseases.

AU2025211521A1Pending Publication Date: 2026-07-23LIFEMINE THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
AU · AU
Patent Type
Applications
Current Assignee / Owner
LIFEMINE THERAPEUTICS INC
Filing Date
2025-01-21
Publication Date
2026-07-23

AI Technical Summary

Technical Problem

Current calcineurin inhibitors (CNIs) used for treating inflammatory-related diseases and disorders, such as pulmonary, skin, and ocular conditions, are associated with significant side effects like nephrotoxicity, CNS toxicity, and patient nonadherence, necessitating the development of novel compounds with improved safety profiles.

Method used

Development of novel N-heterocyclic compounds, including quinoline and isoquinoline moieties, that target calcineurin to treat inflammatory-related diseases and disorders, offering potential alternatives to traditional CNIs.

Benefits of technology

The novel N-heterocyclic compounds provide a safer therapeutic option with reduced side effects, enhancing patient adherence and efficacy in treating inflammatory-related diseases and disorders.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000020_0000
    Figure 00000020_0000
Patent Text Reader

Abstract

The application provides novel N-heterocyclic compounds, such as quinoline or isoquinoline compounds, preferably quinazoline compounds, as calcineurin inhibitors (CNIs,) that provide improved safety profiles, and the pharmaceutical composition and formulation thereof, as well as a method of using the N-heterocyclic compounds for the treatment of, inter alia, an inflammatory-related disease or disorder.
Need to check novelty before this filing date? Find Prior Art